Saturday 17 October 2026
Export AZTA’s income statement to Excel — free account
Azenta, Inc.
AZTA Healthcare Medical Instruments & Supplies
Azenta, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $593.8 million, up 3.55% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 104.4% and free cash flow fell 134.7%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
34.09
2.43
−6.65%
Follow AZTA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.88 | 1.63 | 2.57 | 2.21 | |
P/FCF ratio |
116.96 | 32.39 | 49.39 | 34.28 | |
P/Operating CF |
799.79 | 72.03 | 73.28 | 605.41 | |
P/B ratio |
0.77 | 0.63 | 0.89 | 0.76 | |
Price to Tangible BV |
1.32 | 1.07 | 1.67 | 1.42 | |
EV/Sales |
1.43 | 1.07 | 1.96 | 1.72 | |
EV/EBITDA |
31.24 | 20.25 | 38.90 | 31.13 | |
EV/Operating CF |
23.11 | 10.27 | 18.44 | 14.14 | |
EV/FCF |
88.82 | 21.32 | 37.69 | 26.63 | |
Quick Ratio |
1.75 | 2.03 | 2.10 | 2.08 | |
Current Ratio |
2.50 | 2.83 | 2.92 | 2.98 | |
Net Debt/EBITDA |
(36.48) | 127.09 | (68.25) | (21.35) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.32 | 0.30 | 0.29 | 0.29 | |
Operating CF/Net income |
0.59 | (0.08) | (1.35) | 0.04 | |
Capex/Depreciation |
(0.50) | (0.05) | (0.47) | (0.55) | |
Research and Development Expense of Revenue |
5.49% | 6.51% | 6.18% | 5.19% | |
Selling, General and Administrative Expense of Revenue |
41.67% | 46.88% | 40.78% | 38.76% | |
Intangible Assets out of Total Assets |
0.34 | 0.34 | 0.39 | 0.39 | |
Share Based Compensation of Revenue |
2.99% | 4.39% | 2.73% | 2.62% | |
Graham Net Nets |
0.27 | 0.39 | 0.28 | 0.29 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.78%) | (18.69%) | (4.03%) | (4.49%) | |
Free Cash Flow Yield |
0.85% | 3.09% | 2.02% | 2.92% | |
Revenue per Share |
3.56 | 3.14 | 3.24 | 3.48 | |
Operating CF per Share |
0.03 | 0.29 | 0.45 | 0.05 | |
Capex per Share |
(0.15) | (0.16) | (0.13) | (0.17) | |
Free Cash Flow per Share |
(0.11) | 0.13 | 0.32 | (0.12) | |
Cash per Share |
7.25 | 8.31 | 8.97 | 7.50 | |
Shareholders Equity per Share |
33.35 | 33.75 | 37.34 | 37.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
33.35 | 33.75 | 37.34 | 37.75 | |
Free Cash Flow |
(5.19) | 6.11 | 14.66 | (5.69) | |
Working Capital |
408.78 | 469.79 | 512.69 | 470.67 | |
Capital Expenditures |
(6.64) | (7.40) | (6.19) | (7.86) | |
Net Current Asset Value |
315.27 | 377.77 | 420.30 | 375.74 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.05 | 0.04 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
137.03 | 143.82 | 152.60 | 164.97 | |
Average Payables |
38.68 | 36.15 | 35.25 | 35.53 | |
Average Inventory |
79.79 | 80.92 | 81.73 | 73.14 | |
Average Assets |
1,947.67 | 1,972.91 | 2,057.82 | 2,079.92 | |
Average Common Equity |
1,591.88 | 1,628.08 | 1,716.90 | 1,747.42 |
Columns are period end dates